Incyte Corporation – Graft-versus-host Disease (GVHD)

Access Program Information

To provide ruxolitinib through an expanded access program for the treatment of
graft-versus-host disease (GVHD) in United States to patients who are ineligible or unable
to participate in any actively enrolling Incyte-sponsored clinical studies for ruxolitinib
in the treatment of GVHD.